Profile

Cover photo
The Cheap Investor
55 followers|19,058 views
AboutPostsPhotosVideos

Stream

The Cheap Investor

Shared publicly  - 
 
Oil Prices: Why so Much Volatility? - It’s one of the most volatile stories in the financial world. In August 2016, oil prices rallied from a low of $39.19 to a high of $49.36 on hopes that oil producer talks in September 2016 would curb ballooning supply. By late August, though, oil began to pull back to a low of $42.98. All as U.S. drillers added more oilrigs, as Iraq planned to increase exports of Kirkuk crude by 150,000 barrels a day, and as Nigerian rebels said they were ready for a ce...
It’s one of the most volatile stories in the financial world. In August 2016, oil prices rallied from a low of $39.19 to a high of $49.36 on hopes that oil
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
- So much for the Federal Reserve’s idea that the U.S. economy is prepared for a rate hike… Shortly after the U.S. announced that employers added 155,000 jobs in August 2016 (missing estimates for 181,000) the odds of a September 2016 rate hike dropped to 18% from 82%. Of those jobs, some of the biggest gains were from temporary employment. Bars and restaurants added 34,000 jobs, leisure and hospitality added 29,000 jobs, and retailers added 15,100 jobs.  Meanwhile, the manufacturing secto...
So much for the Federal Reserve’s idea that the U.S. economy is prepared for a rate hike… Shortly after the U.S. announced that employers added 155,000 job
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
EpiPen Price Crisis: Potential Solutions for 3.6 million Americans
“I am running a business. I am a for-profit business. I am not hiding from that.” That was Mylan CEO, Heather Bresch’s recent reaction to the EpiPen cost
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
EpiPen Debate: Why Drug Delivery System is So Expensive - The pharmaceuticals industry is no stranger to controversy. Plagued with runaway drug prices that have drawn the ire of Americans, the industry has come under fire, most recently from Democratic presidential nominee Hillary Clinton. But it’s not just the high cost of drugs that’s upset her. It’s also the high cost of drug delivery systems. Rising prices for EpiPens has resulted in outrage.  When Mylan acquired the EpiPen from Merck i...
The pharmaceuticals industry is no stranger to controversy. Plagued with runaway drug prices that have drawn the ire of Americans, the industry has come un
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Hillary Clinton 2016: Where she stands on taxes - It’s looking like a nose-to-nose fight to the finish. At the moment, 41% of Americans are in favor of Hillary Clinton.  Another 37% backs Donald Trump.  About 10% are in favor of Libertarian candidate Gary Johnson, and another 4% in favor of Green Party candidate Jill Stein. But it’s the main contenders that are generating quite a firestorm about how to turn around our lackluster economy. It’s surely coming down to the wire.  Last Wednesday ...
It’s looking like a nose-to-nose fight to the finish. At the moment, 41% of Americans are in favor of Hillary Clinton. Another 37% backs Donald Trump. Ab
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Chart of Day: Dow 20,000? - Dow Jones 36,000 may remain a pipe dream.  But analyst expectations for 20,000 could soon be reality.  In fact, as of last week, the consensus one-year estimate on Wall Street is now 20,003.93, up from an earlier projection of 19,914.  And it’s not as farfetched as you’d think especially in such a low interest rate environment with no real rate hike threats on the horizon. Despite true unemployment numbers, poor GDP, negative wage growth, weak productivity, slowi...
Dow Jones 36,000 may remain a pipe dream. But analyst expectations for 20,000 could soon be reality. In fact, as of last week, the consensus one-year est
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Chart of Day: Groupon (GRPN) Returns 113% - The Cheap Investor has traded Groupon Inc. (GRPN) quite a few times. The most recent recommendations were at just $2.79 a share in the December 2015 issue, at $4.20 in the March 2016 issue, and at $3.35 in the July 2016 issue.  Shares have since rallied to a high of $5.94, handing subscribers potential gains of 113%, 41% and 77%.  All after the company beat EPS estimates with a one-cent loss.  Second quarter revenue jumped 2% to $756 million, whic...
The Cheap Investor has traded Groupon Inc. (GRPN) quite a few times. The most recent recommendations were at just $2.79 a share in the December 2015 issue,
1
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Chart of Day: Rigel Pharmaceuticals (RIGL) soars 108% - After a sell-off in the biotech sector, we found a great deal of severely undervalued names trading at extremely low prices. It’s part of the reason why we recommended Rigel Pharmaceuticals (RIGL) at just $1.95 a share in the April 2016 issue of The Cheap Investor.  Shares of RIGL are now up 108% after the company announced favorable data on its oral spleen tyrosine kinase inhibitor, fostamatinib, for the treatment of adult chronic/per...
After a sell-off in the biotech sector, we found a great deal of severely undervalued names trading at extremely low prices. It’s part of the reason why we
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Chart of Day: Bovie Medical (BVX) Soars 159% - The summer was one of the most profitable on record for us, too.  In fact, since May, here are just some of the wins collected by subscribers: Bovie Medical Corporation (BVX) up 159% Rigel Pharmaceuticals (RIGL) up 29% Goldfield Corporation (GV) up 106% MeetMe Inc. (MEET) up 135% Adverum Biotechnologies (ADVM) up 37% Groupon Inc. (GRPN) up 77% Supreme Industries (STS) up 33% Fate Therapeutics (FATE) up 82% Trio-Tech International (TRT) up 26% I...
The summer was one of the most profitable on record for us, too. In fact, since May, here are just some of the wins collected by subscribers: Bovie Medica
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Chart of Day: The Biotech M&A Boom Continues - In early April 2016, we noted, “Biotech may have had a rough start to the year, lagging many other sectors. But don’t count it out just yet.  In fact, buy all you can.  The same strong catalysts and fundamentals are still firmly in place. Even though the first quarter of 2016 showed slower M&A activity, I can assure you the trend is far from over.” As it turns out, we were absolutely right. Just this week, Pfizer agreed to buy Medivation (MDVN)...
In early April 2016, we noted, “Biotech may have had a rough start to the year, lagging many other sectors. But don’t count it out just yet. In fact, buy
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Why Are Billionaires Piling Into This 4000% Growth Industry?
It’s my favorite time of year. Yes, I live in Scottsdale, Arizona. It’s August. The heat is unbearable. The town grounds to a halt when it passed 110 degre
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Fair Warning: Longest Losing Streak in 37 years - U.S. economic growth is “pretty damn good.” That’s what billionaire investor Warren Buffett said in an interview this week. While he admitted GDP of less than 2% doesn’t match the quicker pace of decades past, he still believes the economy is just fine. When it comes to productivity, he noted: “If you don’t improve productivity, you don’t go anyplace. And fortunately, we have a system—we’re in the early innings of it, but we have a system wh...
U.S. economic growth is “pretty damn good.” That’s what billionaire investor Warren Buffett said in an interview this week. While he admitted GDP of less t
1
Add a comment...
Story
Tagline
Founded in 1981 by Bill Mathews, The Cheap Investor newsletter is all about discovering quality stocks trading for less than $5 per share.
Introduction
Since 1981, The CHEAP Investor newsletter has been an intelligent and straightforward guide to choosing low-price quality stocks and has helped thousands of investors make profitable investment decisions. Subscribers get the information that they need to purchase stocks with great profit potential at the lowest price. The CHEAP Investor was rated the #1 Best Performing Market Letter for the five-year period ending November 2006, by Select Information Exchange and one of the four best small stock advisories in America by the League of American Investors.


Bill Mathews
Recognized as one of the foremost authorities on investing in small-cap stocks, Bill Mathews has been a frequent guest on radio and television shows nationwide such as CNBC. He has been interviewed by major newspapers and magazines including the Wall Street Journal, Business Week, Barrons and the Chicago Tribune. Bill Mathews is the author of the book "Making Big Money in Small Stocks" which describes specific techniques for analyzing stocks easily and profitably as well as determining what might affect a stock's profit potential. Mr. Mathews also taught securities analysis for the MBA program at the Keller Graduate School of Management, and spent 15 years teaching business and investment courses at Triton College.
Contact Information
Contact info
Phone
(877) 306-4256
Email